IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort
Cancer Communications · 2026
DOI: 10.34133/cancomm.0015 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Communications, 2026. Verfasst von Javier Martin-Broto und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Nivolumab, Sunitinib, Antineoplastic Combined Chemotherapy Protocols, Sarcoma, Clear Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: GEIS, ISG, UCL.
Abstract (Originalsprache)
Background
Clear cell sarcoma (CCS) is an ultrarare sarcoma driven by a specific chromosomal translocation, most commonly the EWS RNA binding protein 1–activating transcription factor 1 fusion ( EWSR1::ATF1 ), for which chemotherapy shows limited activity, with a median progression-free survival (PFS) of approximately 3 months in retrospective series. In the present trial, a CCS cohort was selected based on signals of activity observed in the IMMUNOSARC I phase I/II trial evaluating nivolumab in combination with sunitinib in sarcomas.
Methods
Patients aged 12 to 80 years with advanced, progressive, and measurable CCSs were enrolled after central pathology review, and molecular confirmation of an EWSR1 rearrangement was required. Sunitinib was administered at 37.5 mg/d during the first 2 weeks and then at 25 mg/d along with nivolumab at 240 mg every 2 weeks. The primary end point was the 6-month PFS rate, defined under the null (H 0 ) and alternative (H 1 ) hypotheses as 25% and 55%, respectively. Under Simon’s 2-stage minimax design (α = 0.05, power = 0.90), a minimum of 10 of 23 patients needed to be progression-free at 6 months.
Results
At the time of cutoff, 23 patients were evaluable for the primary end point. With a median follow-up of 23.0 months (95% confidence interval [CI], 10.0 to 35.0 months), the 6-month PFS rate was 50.1% (95% CI, 29.1% to 71.1%), while the median PFS was 6.2 months (95% CI, 3.0 to 9.3 months). Of 21 patients who underwent at least 1 radiological assessment, 3 (14.3%) achieved partial response, 14 (66.7%) had stable disease, and 4 (19.0%) had progressive disease. The median overall survival was 17.0 months (95% CI, 95% CI, 5.6 to 28.5 months). The main all-grade drug-related toxicities were lymphocytopenia (46.2%), leukopenia (38.5%), anemia (38.5%), and neutropenia (38.5%). Two grade 4 toxicities were reported: Alanine aminotransferase increased and ischemia (each 3.8%), while 31 grade 3 toxicities occurred, with anemia and lymphocytopenia being the most common (each 23.1%). A higher programmed death-ligand 1 composite score was associated with better PFS: 21.2 months (95% CI, 6.0 to 36.4 months) versus 4.2 months (95% CI, 2.7 to 5.6 months), P = 0.045.
Conclusions
While further studies are needed, initial findings suggest that nivolumab plus sunitinib could be a valuable addition to the current armamentarium for CCS management.
Trial registration
ClinicalTrials.gov ID NCT03277924 (date of registration: 2017 September 6).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
- University Hospital General de Villalba, Madrid, Spain.
- Fundación Jiménez Díaz Health Research Institute, Autonomous University of Madrid, Madrid, Spain.
- Department of Medical Oncology, University College London Hospital, London, UK.
- Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Ortopedico Rizzoli, Bologna, Italy.
- Department of Medical Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA.
ORCID-Profile: Javier Martin-Broto
Förderung
- GEIS
- ISG
- UCL
- Bristol-Myers Squibb
- Pfizer
- APSATUR
Zitieren
APA
Martin-Broto, J., Strauss, S. J., Palmerini, E., Valverde, C., Sebio, A., Redondo, A., Stacchiotti, S., Grignani, G., Aliberti, S., Diaz-Beveridge, R., Billalabeitia, E. G., Cruz, J., Carrasco-Garcia, I., Ibrahim, T., Diaz-Martin, J., Salguero-Aranda, C., Gutierrez, A., Mayordomo-Aranda, E., Ramos, R., …, & Moura, D. S. (2026). IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. Cancer Communications. https://doi.org/10.34133/cancomm.0015
Vancouver
Martin-Broto J, Strauss SJ, Palmerini E, Valverde C, Sebio A, Redondo A, et al. IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. Cancer Communications. 2026. doi:10.34133/cancomm.0015
BibTeX
@article{MartinBroto2026,
author = {Martin-Broto, Javier and Strauss, Sandra J and Palmerini, Emanuela and Valverde, Claudia and Sebio, Ana and Redondo, Andres and Stacchiotti, Silvia and Grignani, Giovanni and Aliberti, Sandra and Diaz-Beveridge, Roberto and Billalabeitia, Enrique Gonzalez and Cruz, Josefina and Carrasco-Garcia, Irene and Ibrahim, Toni and Diaz-Martin, Juan and Salguero-Aranda, Carmen and Gutierrez, Antonio and Mayordomo-Aranda, Empar and Ramos, Rafael and Merino, Jose and Collini, Paola and Tirabosco, Roberto and Bague, Silvia and Romagosa, Cleofe and Carrera, Maria Augusta and Ledesma, Patricio and Hindi, Nadia and Moura, David Silva},
title = {IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort},
journal = {Cancer Communications},
year = {2026},
doi = {10.34133/cancomm.0015}
}
EUVIMED